

### **REMARKS**

Claims 116 and 120 have been amended to clarify that the compositions used in the method themselves contain isolated short RNA molecules. By inserting the terms “composition that contains” into claim 116 and clarifying that the compositions of claim 120 actually contain the SRMs, it is clear that the SRMs are supplied as such.

Applicants are also proposing new claims 125-130 which correspond to existing claims 116-117, 119-120, 122 and 124. These claims are directed to effecting gene silencing by introducing at least one vector that generates the same SRMs as are described in the present claims. Applicants note that the Office had interpreted claims 116 and 120 as previously pending as including introduction of such vectors. Support for this is found, in a number of places in the specification, including page 4, lines 20-25; page 10, lines 7-18, and page 13, line 25 to page 21, line 32. As discussed below, as the claims have been already interpreted to include this subject matter, it does not constitute new matter.

Claims 119, 124, 127 and 130 have been amended to add viruses to the list of target genes. This is supported in the specification on pages 25-26 which demonstrates RNA media-aided defense against viral infection. Since viruses are not considered organisms in the sense the term “organism” is used, for example, in claim 120, the language has been changed to eliminate this term, thus to accommodate the possibility that the target gene may be a viral gene.

In all, no new matter has been added and entry of the amendment is respectfully requested.

Applicants greatly appreciate the withdrawal of the rejections previously made and address the outstanding rejections as follows. All of the rejections are made over the art.

#### **Anticipation**

Claims 116-124 were rejected as assertedly anticipated by Graham (U.S. 6,573,099). It was agreed at the interview that the proposed amendment disposes of this rejection. The rejection was

based on an interpretation of claims 116 and 120 that is no longer appropriate with regard to the amended claims. Accordingly, this basis for rejection as to these claims may be withdrawn.

However, as new claims 125-130 are directed to the subject matter that elicited this rejection, it is assumed that the rejection would have been addressed to them.

According to the Office, Graham teaches genetic constructs and vectors that produce the short RNAs, consisting of 20-24 nucleotides, required by the present claims. Applicants believe this interpretation of Graham's teaching is in error for the reasons that follow.

In applicants' view, the Office is improperly concluding that Graham is teaching that the expressed RNA molecules will be only 20-30 nucleotides long. Graham does not teach this. Graham in fact teaches the construction of vectors that express much longer RNA sequences and makes it clear that it is only the portions of these longer RNA's that match the targeted gene that can be 20-30 nucleotides. As noted in column 6, preferred structural gene "components" of a synthetic gene of the invention comprise at least about 20-30 nucleotides in length derived from the gene intended to be silenced. These are the structural gene components of the synthetic gene, not the synthetic gene itself. Even the structural gene component can have additional sequence as it "comprises" at least about 20-30 nucleotides derived from the intended gene (see column 6, lines 25-40).

Similarly, the claims in Graham make clear that sequences of 20-30 nucleotides are simply subsequences of longer RNA. All of the independent claims in Graham, *i.e.*, claims 1-5, 7 and 10, employ a genetic construct which "comprises" at least 2 copies of a structural gene sequence where in turn, the structural gene sequence "comprises" a nucleotide sequence substantially identical to at least a region of the target gene. The dependent claims, 11-12, refer to the length of the region of the target gene as 20-30 nucleotides long. It is clear that Graham is claiming constructs that are

transcribed into sense and antisense RNA molecules which are not themselves limited to 20-30 nucleotides but merely contain sequences that correspond/are complementary to a gene region of this size.

As applicants are certain the Office is aware, claims should be interpreted in light of the specification, and not in a vacuum. This guidance was offered by the Federal Circuit *en banc* in *Phillips v. AWH Corp.*, 415 F3d 1303, 75 USPQ2d 1321 (Fed. Cir. *en banc* 2005).

The foregoing interpretation is thus in accordance with the holding in *Phillips*, as it is consistent with the specification of Graham. None of the examples provided by Graham teach the generation of short RNA molecules; all are composed of longer sequences of DNA to be transcribed. There is no suggestion anywhere in Graham that any RNA molecules that “consist of” 20-30 nucleotides be generated. In fact, multiple alternatives for expression systems are disclosed all of which result in production of longer RNA molecules even if discrete portions of the gene were inserted into the vectors. Graham, in column 13, lines 48-52, suggests a “particularly preferred” embodiment where the terminator is an SV40 polyadenylation signal or the HSVtk polyadenylation signal, or the lacZ  $\alpha$ -terminator. All of these result in extensions in the RNA molecules formed in the transcripts, so clearly Graham is not concerned with generating discrete RNA molecules that consist of 20-30 nucleotides, since the portion corresponding/complementary to a region of a target gene must itself be 20-30 nucleotides. The extensions effected by the terminator thus mandate longer sequences than 20-30 nucleotides.

Graham also fails to teach or suggest any advantages of using SRMs wherein the molecules are 20-30 nucleotides in length, namely, the avoidance of inducing the interferon response, which occurs when long dsRNA is introduced into mammalian cells, as noted in the enclosed paper, Elbashir, *et al* which cites, on page 494, a 1998 paper that describes this effect. In addition, use of

the SRMs of the present invention minimizes so-called “off-site” or “off target” effects because there are no extraneous sequences in the silencing inducing molecules which could target genes other than the intended target gene.

For the reasons set forth above, Graham does not anticipate or render obvious new claims 125-130.

#### The Obviousness Rejections

Claims 116-124 were rejected as assertedly unpatentable over the combination of Fire, *et al.* (U.S. 6,506,559) in view of Graham. The Examiner has kindly clarified that this rejection addresses the embodiment encompassed by the claims wherein the RNA molecules themselves are introduced directly into plant cells.

Claim 10 of Fire is cited as evidence that in effect, claim 1 of Fire encompasses RNA molecules that are shorter than 25 bases in length. Respectfully, applicants believe this is not the case.

Claim 1 of Fire refers to a double-stranded RNA molecule with a first strand “consisting essentially of” a ribonucleotide sequence which corresponds to a nucleotide sequence of the target gene and a second strand “consisting essentially of” a ribonucleotide sequence which is complementary to the nucleotide sequence of the target gene. The language “consisting essentially of” is properly interpreted as different from “consisting of.” “Consisting essentially of” is semi-open language – “consisting essentially of” permits inclusion of additional components that are tangential to the essential portion of the composition. Thus, by using the phrase “consisting essentially of” to describe the corresponding or complementary nucleotide sequence, the claim language is open to additional sequence which is not complementary to or does not correspond to sequences in the targeted gene.

This interpretation is consistent with the interpretation placed on this phrase by the courts. For example, in *P.P.G. Industries v. Guardian Industries Corp.*, 156 F3d 1351, 48 USPQ2d 1351 (Fed. Cir. 1998) the Court stated that this language is partially open and necessarily includes the listed component, but is open to unlisted components that do not affect the novel properties of the listed ones. It is considered a “middle ground” between “consists of” and “comprises.”

Claim 10 actually clarifies this by using the open language “comprises” at least 25 bases which correspond to target gene, or “comprises” at least 25 bases that are complementary to the target gene. If the open language “comprises” is used in claim 10, then this necessarily indicates that in claim 1 additional sequence can be present. This does not imply that the double-stranded RNA itself can be shorter.

This interpretation is entirely consistent with the specification of Fire which, at column 8, line 6, states that “the length of the “identical nucleotide sequences” may be at least 25, 50, 100, 200, 300 or 400 bases.” Column 8 does not state that the double-stranded RNA itself may be at least 25 bases. Other sections of the Fire disclosure are noted by the Office, but the only mention of a length of nucleotide sequences that applicants are able to find is in column 8, line 6.

As required by *Phillips* cited above, the interpretation of the claims must be consistent with the specification, and it is. Clearly the Fire specification contemplates much longer sequences where only the gene-matching portions might be at least 25 nucleotides in length, as set forth above.

Although claim 12 is not mentioned in the rejection, it was discussed at the interview. Claim 12 also uses the semi-open language “consisting essentially of” in describing the sequences complementary to or corresponding to the target gene, thus allowing for additional sequences. Claim 15 dependent thereon refers to the double-stranded RNA “structure” as at least 25 bases in

length. Applicants find no explicit antecedent basis for the word “structure” in claim 12 and interpret this term, in light of the specification as described above, and in light of the semi-open language in claim 12, as referring to the corresponding and complementary portions of a longer molecule. Thus, the “structure” is that of the relevant complementary/corresponding sequences themselves, not the entire RNA molecule.

Indeed, of course, as the Office is aware, the understanding that short RNA molecules of less than 25 nucleotides in sequence could themselves initiate post-transcriptional gene silencing, is the contribution of the present inventors. In fact, it is also considered to be the contribution of the present inventors that molecules in the size range of 25-30 nucleotides themselves initiate post-transcriptional gene silencing, but this is a battle we reserve for another day in a continuation application in favor of allowance of the claims limited to 20-24 nucleotides in length as presented herein.

Thus, it is not correct to infer that Fire discloses RNA molecules that are shorter than 25 bases in length that can induce gene silencing. Consistent with this, it is (correctly) not asserted by the Office that Fire anticipates the invention as claimed.

However, the Office asserts that it would have been obvious to use the method of Fire to introduce into plants double-stranded RNA molecules to inhibit the expression of a target gene by making the RNA molecules 20-24 nucleotides long because Graham teaches that expressed RNA sequences that repress a target gene of interest can be 20-30 nucleotides long.

As discussed extensively above, this is not what Graham actually discloses.

Taken together, Fire and Graham do not suggest a method of using actual short RNA molecules directly to silence genes. Neither Fire nor Graham teaches short RNA molecules *per se*.

Each of them simply require RNA molecules with regions of complementarity that are of relatively modest length. Accordingly, this basis for rejection may be withdrawn. It is urged, in addition, that this basis of rejection is also not applicable to claims 125-130 drawn specifically to methods of inducing silencing using vectors which produce these SRMs when introduced into cells for the same reasons as outlined above.

Claims 116-124 were rejected as assertedly unpatentable over Brown, *et al.* (U.S. 6,723,987).

Applicants have reviewed the sections noted by the Office in Brown and fail to find any suggestion that fragments or RNA molecules that can be used in co-suppression strategies can include those that are in the size range of 20-24 nucleotides. Column 3, lines 49-67, indicate that among other techniques for reducing expression of an enzyme in the pathway for the synthesis of gibberellin, one can use an antisense construct, a ribozyme, triplex DNA, or can effect co-suppression. The column then goes on to say that in order to alter gibberellin levels, suppression of expression of an enzyme could be conducted by “antisense expression of a sequence that comprises at least 12 contiguous nucleotides, etc.” There is no mention of any length of fragment for conducting co-suppression.

Column 16, line 66 to column 20, line 27, merely list promoters that can be used “to express the protein or protein fragment of choice.” Applicants are unable to find anything in this section that specifies the length of an RNA molecule that might be used to effect co-suppression. Similarly, in column 21, lines 57-63, there is simply a discussion of various vector systems with no specification of the length of RNA molecules that might be encoded.

Thus, in addition to failing to suggest that both antisense techniques and co-suppression be conducted simultaneously (indeed implying that only one or the other should be conducted)\*, Brown fails to teach or suggest the use of any short sense RNA molecules. The specification of short sequences for antisense techniques is insufficient to suggest short RNA molecules for the conduct of co-suppression. It is also insufficient to teach the method claimed in this application wherein both sense and antisense short RNA molecules at the same abundance are utilized to induce silencing. It would appear that in column 5, beginning at line 65, constructs which presumably result in co-suppression are described and they are required to contain at least 100 base pairs corresponding with the gene to be silenced.

Thus, Brown fails to suggest the claimed method.

#### Conclusion

The rejection of claims 116-124 for anticipation by Graham has been mooted by amendment to these claims. A similar rejection of with regard to new claim 125-130, which presumably would have been made, would be in error because Graham fails to suggest generating RNA molecules of the length required by the claims. Graham only teaches generation of long RNA molecules that contain corresponding/complementary *subsequences* of 20-30 nucleotides in length.

The rejection over Fire combined with Graham may be withdrawn as Fire does not suggest employing RNA molecules consisting of 25 nucleotides or less but rather RNA molecules whose complementary/corresponding *subsequences* are of at least this length. Graham, similarly, fails to teach, suggest or enable use of constructs which would result in the production of SRMs in the size range claimed in the present claims.

---

\* It is not clear how simultaneous conduct of co-suppression and antisense interference, as suggested by the Office, would lead to the method of the present invention since co-suppression already requires both sense and antisense strands.



Brown does not suggest the invention as RNA molecules in the size range required by the present claims are suggested only in employing antisense methods, not in employing co-suppression methods. In any event, Brown does not suggest both antisense and co-suppression methods simultaneously, and in Brown's description of co-suppression, at least 100 base pairs are required.

For the reasons set forth above, it is believed that claims 116-130 are in a position for allowance.

Again, applicants wish to express their appreciation to Examiners Mehta and Grunberg for the helpful discussion at the interview.

Should minor issues remain that could be resolved by phone, a call to the undersigned is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **Docket No. 616292000111**.

Respectfully submitted,

Dated: May 2, 2008

By: /Kate H. Murashige/  
Kate H. Murashige  
Registration No.: 29,959  
MORRISON & FOERSTER LLP  
12531 High Bluff Drive, Suite 100  
San Diego, California 92130-2040  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125

ogy), respectively. Staining specificity was controlled by single staining, as well as by using secondary antibodies in the absence of the primary stain.

## Generation of target cells

Target cells displaying a membrane-integrated version of either wild-type HEL or a mutant<sup>18</sup> exhibiting reduced affinity for HyHEL10 (<sup>18</sup>R<sup>1</sup>, D<sup>23</sup>, G<sup>23</sup>, N<sup>23</sup>) designated HEL<sup>18</sup> were generated by transfecting mouse J558L plasmacytoma cells with constructs analogous to those used<sup>18</sup> for expression of soluble HEL/HEL<sup>18</sup>, except that 14 Ser/ Gly codons, the H2K\* transmembrane region, and a 23-codon cytoplasmic domain were inserted immediately upstream of the termination codon by polymerase chain reaction. For mHEL-GFP, we included the EGFP coding domain in the Ser/ Gly linker. Abundance of surface HEL was monitored by flow cytometry and radiolabelled-antibody binding using HyHEL5 and D1.1 HEL-specific monoclonal antibodies, for which mutant HELs used in this work show unaltered affinities<sup>18</sup>.

## Interaction assays

For B-cell/target interaction assays, splenic B cells from 3–83 or MD4 transgenic mice<sup>20,21</sup> carrying IgM + IgD BCRs specific for HEL or H2K\*H2K\* were freshly purified on Lympholyte and incubated with a twofold excess of target cells in RPMI, 50 mM HEPES pH 7.4, for the appropriate time at 37°C before being applied to polystyrene-coated slides. Cells were fixed in 4% paraformaldehyde/PBS or methanol and permeabilized with PBS/0.1% Triton X-100 before immunofluorescence. We acquired confocal images using a Nikon E800 microscope attached to BioRad Radience Plus scanning system equipped with 488-nm and 543-nm lasers, as well as differential interference contrast for transmitted light. GFP fluorescence in living cells in real time was visualized using a Radiance 2000 and Nikon E800 inverted microscope. Images were processed using BioRad LaserSharp 1024 or 2000 software to provide single plane images, confocal projections or slicing.

## Antigen presentation

Presentation of HEL epitopes to T-cell hybridomas 2G7 (specific for I-E<sup>b</sup>[HEL<sup>1–10</sup>]) and 1B5 (specific for I-E<sup>b</sup>[HEL<sup>108–111</sup>]) by transfectants of the LK35.2 B-cell hybridomas expressing an HEL-specific IgM BCR was monitored as described<sup>18</sup>.

Received 12 December 2000; accepted 30 March 2001.

1. Lanzavecchia, A. Antigen-specific interaction between T and B cells. *Nature* 314, 537–539 (1985).
2. Klaus, G. & Humphrey, J. H., Kunkl, A. & Donaghy, D. W. The follicular dendritic cell: its role in antigen presentation in the generation of immunological memory. *Immunol. Rev.* 53, 1–28 (1980).
3. Tew, J. G., Kozes, M. H., Burton, G. F. & Szalai, A. K. Follicular dendritic cells as accessory cells. *J. Immunol.* 157, 185–191 (1996).
4. Kozes, M. H., Gray, D., Scheidegger, D. & Julius, M. Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/801 and upregulation of major histocompatibility complex II molecules. *J. Exp. Med.* 178, 2055–2064 (1993).
5. Schmal, W. & Reich, M. Monoclonal and polyclonal complexes of the B cell antigens receptors. *Immunology* 13, 5–14 (2000).
6. Taylor, R. B., Duffus, W. P. H., Raff, M. C. & de Petris, S. Redistribution and pinocytosis of lymphocyte surface immunoglobulin molecules induced by anti-immunoglobulin antibody. *Nature* 235, 225–227 (1971).
7. Schöten, G. F. & Unanue, E. R. Capturing and the lymphocyte: models for membrane reorganization. *J. Immunol.* 151, 1549–1551 (1977).
8. Cheng, R. C., Dykstra, M. L., Mitchell, R. N. & Pierce, S. K. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. *J. Exp. Med.* 190, 1549–1560 (1999).
9. Weintraub, B. C. Entry of B cell receptor into signaling domains is inhibited in tolerant B cells. *J. Exp. Med.* 191, 1443–1448 (2000).
10. Batist, P. D. & Neuberger, M. A. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. *Immunol. Rev.* 6, 751–759 (1998).
11. Nemazee, D. & Burki, K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. *Nature* 337, 561–566 (1989).
12. Hartley, S. B. et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. *Nature* 353, 726–729 (1991).
13. Dustin, M. L. et al. Low efficiency of interaction of human and rat T cell adhesion molecule CD2 with its ligands allows adhering molecules to achieve high physiological affinity. *J. Biol. Chem.* 272, 30889–30898 (1997).
14. Lang, J. et al. B cells are exquisitely sensitive to central tolerance and receptor editing by ultraviolet irradiation. *Nature* 353, 1685–1687 (1996).
15. Valitutti, S., Muller, S., Celis, E., Lanzavecchia, A. Serial triggering of many T cell receptors by a few peptide–MHC complexes. *Nature* 375, 146–151 (1995).
16. Monks, C. R., Freiberg, N. A., Kupfer, H., Scialy, N. & Kupfer, A. Three-dimensional sampling of supramolecular activation clusters in T cells. *Nature* 395, 62–66 (1998).
17. Walting, C. & Davis, M. M. A receptor/tyrosine kinase movement triggered by continuation during T cell activation. *Science* 282, 2266–2269 (1998).
18. Grubisic, A. et al. The immunological synapse: a molecular machine controlling T cell activation. *Science* 285, 321–327 (1999).
19. Leung, Q., Zaru, R., Laroche, T., Muller, S. & Valitutti, S. Exclusion of CD45 from the T-cell receptor signaling area in antigen-stimulated T lymphocytes. *Curr. Biol.* 10, 277–280 (2000).
20. Cagan, R. L., Kramer, H., Hart, A. C. & Zipursky, S. L. The trade of severities and severities interaction: internalization of a transmembrane ligand. *Cell* 69, 393–399 (1992).
21. Huang, J. F. et al. TCR-mediated internalization of peptide–MHC complexes acquired by T cells. *Science* 286, 952–954 (1999).
22. Hwang, J. et al. T cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived from antigen-presenting cells. *J. Exp. Med.* 191, 1137–1148 (2000).
23. Batista, F. D. & Neuberger, M. A. B cells extract and present immobilized antigens: implications for affinity discrimination. *EMBO J.* 19, 513–520 (2000).
24. Catten, L. A., Lakey, E. K., Jettich, M. L., Margraf, E. & Pierce, S. K. Anti-immunoglobulin

- augments the B-cell antigen-presentation function independently of internalization of receptor-antigen complexes. *Proc. Natl. Acad. Sci. USA* 82, 5890–5894 (1985).
25. Siermash, K., Eickelberg, R., Kohls, S. & Clark, M. R. Signals from the B lymphocyte antigen receptor regulate MHC class II containing late endosomes. *J. Immunol.* 160, 5203–5208 (1998).
26. Serre, K. et al. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. *J. Immunol.* 161, 4009–4017 (1998).
27. Goss, S. M., Lenz, A. D., Parrington, J. & Kim, J. Transformation of growth factor-dependent myeloid stem cells with retroviral vectors carrying c-myc. *Oncogene* 737–751 (1990).
28. Russell, D. M. et al. Peripheral deletion of self-reactive B cells. *Nature* 354, 308–311 (1991).
29. Goodnow, C. C. et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. *Nature* 334, 676–682 (1988).
30. Altmann, V. R., Khamis, A. A., Williams, G. T., Adorini, L. & Neuberger, M. A. Acceleration of intracellular targeting of antigen by the B cell antigen receptor: importance depends on the nature of the antigen-antibody interaction. *EMBO J.* 16, 3553–3562 (1997).

Supplementary information is available on Nature's World Wide Web site (<http://www.nature.com>) or as paper copy from the London editorial office of Nature.

## Acknowledgements

We thank B. Amos and S. Reichelt for help and advice with confocal microscopy, and S. Munro for helpful discussions. We are indebted to those who provided antibodies, transgenic mice and cell lines. E.D.B. and D.L. were supported by the Arthritis Research Campaign and Studienstiftung des deutschen Volkes, respectively.

Correspondence and requests for materials should be addressed to E.D.B. (e-mail: edb@mrnc-immc.ac.uk) or M.S.N. (e-mail: msn@mrnc-immc.ac.uk).

# Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Sayda M. Elbashir\*, Jens Harborth\*, Winfried Lendeckel\*, Abdullah Yalcin\*, Klaus Weber† & Thomas Tuschli\*

\* Department of Cellular Biochemistry, and † Department of Biochemistry and Cell Biology, Max-Planck-Institute for Biophysical Chemistry, Am Fassberg 11, D-37077 Göttingen, Germany

RNA interference (RNAi) is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene<sup>1–4</sup>. The mediators of sequence-specific messenger RNA degradation are 21- and 22-nucleotide small interfering RNAs (siRNAs) generated by ribonuclease III cleavage from longer dsRNAs<sup>5–9</sup>. Here we show that 21-nucleotide siRNA duplexes specifically suppress expression of endogenous and heterologous genes in different mammalian cell lines, including human embryonic kidney (293) and HeLa cells. Therefore, 21-nucleotide siRNA duplexes provide a new tool for studying gene function in mammalian cells and may eventually be used as gene-specific therapeutics.


Uptake of dsRNA by insect cell lines has previously been shown to 'knock-down' the expression of specific proteins, owing to sequence-specific, dsRNA-mediated mRNA degradation<sup>6,10–12</sup>. However, it has not been possible to detect potent and specific RNA interference in commonly used mammalian cell culture systems, including 293 (human embryonic kidney), NIH/3T3 (mouse fibroblast), BHK-21 (Syrian hamster kidney), and CHO-K1 (Chinese hamster ovary) cells, applying dsRNA that varies in size between 38 and 1,662 base pairs (bp)<sup>10,12</sup>. This apparent lack of RNAi in mammalian cell culture was unexpected, because RNAi exists in mouse oocytes and early embryos<sup>13,14</sup>, and because RNAi-related, transgene-mediated co-suppression was also observed in cultured Rat-1 fibroblasts<sup>15</sup>. But it is known that dsRNA in the cytoplasm of mammalian cells can trigger profound physiological

reactions that lead to the induction of interferon synthesis<sup>16</sup>. In the interferon response, dsRNA > 30 bp binds and activates the protein kinase PKR<sup>17</sup> and 2',5'-oligoadenylate synthetase (2',5'-AS)<sup>18</sup>. Activated PKR stalls translation by phosphorylation of the translation initiation factors eIF2 $\alpha$ , and activated 2',5'-AS causes mRNA degradation by 2',5'-oligoadenylate-activated ribonuclease L. These responses are intrinsically sequence-nonspecific to the inducing dsRNA.

Base-paired 21- and 22-nucleotide (nt) siRNAs with overhanging 3' ends mediate efficient sequence-specific mRNA degradation in lysates prepared from *Drosophila* embryos<sup>19</sup>. To test whether siRNAs are also capable of mediating RNAi in cell culture, we synthesized 21-nt siRNA duplexes with symmetric 2-nt 3' overhangs directed against reporter genes coding for sea pansy (*Renilla reniformis*, RL) and two sequence variants of firefly (*Photinus pyralis*, GL2 and GL3) luciferases (Fig. 1a, b). The siRNA duplexes were co-transfected with the reporter plasmid combinations pGL2/pRL or pGL3/pRL into *Drosophila* S2 cells or mammalian cells using cationic liposomes. Luciferase activities were determined 20 h after transfection. In *Drosophila* S2 cells (Fig. 2a and b), the specific inhibition of luciferases was complete and similar to results previously obtained for longer dsRNAs<sup>6,10,12,19</sup>. In mammalian cells, where the reporter genes were 50- to 100-fold more strongly expressed, the specific suppression was less complete (Fig. 2c-j). In NIH/3T3, monkey COS-7 and HeLa S3 cells (Fig. 2c-h), GL2 expression was reduced 3-

to 12-fold, GL3 expression 9- to 25-fold, and RL expression 2- to 3-fold, in response to the cognate siRNAs. For 293 cells, targeting of RL luciferase by RL siRNAs was ineffective, although GL2 and GL3 targets responded specifically (Fig. 2i and j). The lack of reduction of RL expression in 293 cells may be because of its expression, 5- to 20-fold higher than any other mammalian cell line tested and/or to limited accessibility of the target sequence due to RNA secondary structure or associated proteins. Nevertheless, specific targeting of GL2 and GL3 luciferase by the cognate siRNA duplexes indicated that RNAi is also functioning in 293 cells.

The 2-nucleotide 3' overhang in all siRNA duplexes was composed of (2'-deoxy) thymidine, except for uGL2, which contained



**Figure 1** Reporter constructs and siRNA duplexes. **a**, The firefly (*Pp-luc*) and sea pansy (*Rr-luc*) luciferase reporter-gene regions from plasmids pGL2-Control, pGL3-Control, and pRL-TK (Promega) are illustrated; simian virus 40 (SV40) promoter (prom); SV40 enhancer element (enh.); SV40 late polyadenylation signal (polyA); herpes simplex virus (HSV) thymidine kinase promoter, and two introns (lines) are indicated. The sequence of GL3 luciferase is 95% identical to GL2, but RL is completely unrelated to both. Luciferase expression from pGL2 is approximately 10-fold lower than from pGL3 in transfected mammalian cells. The region targeted by the siRNA duplexes is indicated as black bar below the coding region of the luciferase genes. **b**, The sense (top) and antisense (bottom) sequences of the siRNA duplexes targeting GL2, GL3, and RL luciferase are shown. The GL2 and GL3 siRNA duplexes differ by only three single-nucleotide substitutions (boxed in grey). As nonspecific control, a duplex with the inverted GL2 sequence, invGL2, was synthesized. The 2-nucleotide 3' overhang of 2'-deoxythymine is indicated as TT; uGL2 is similar to GL2 siRNA but contains ribo-uridine 3' overhangs.

**Figure 2** RNA interference by siRNA duplexes. Ratios of target to control luciferase were normalized to a buffer control (Bu, black bars); grey bars indicate ratios of *Photinus pyralis* (*Pp-luc*) GL2 or GL3 luciferase to *Renilla reniformis* (*Rr-luc*) RL luciferase (left axis), white bars indicate RL to GL2 or GL3 ratios (right axis). **a, c, e, g** and **i**, Experiments performed with the combination of pGL2-Control and pRL-TK reporter plasmids; **b, d, f, h** and **j**, experiments performed with the combination of pGL3-Control and pRL-TK reporter plasmids. The cell line used for the interference experiment is indicated at the top of each plot. The ratios of *Pp-luc*/Rr-luc for the buffer control (Bu) varied between 0.5 and 1.0 for pGL2/pRL, and between 0.03 and 1 for pGL3/pRL, respectively, before normalization and between the various cell lines tested. The plotted data were averaged from three independent experiments  $\pm$  s.d.


uridine residues. The thymidine overhang was chosen because it reduces costs of RNA synthesis and may enhance nuclease resistance of siRNAs in the cell culture medium and within transfected cells. As in the *Drosophila in vitro* system (data not shown), substitution of uridine by thymidine in the 3' overhang was well tolerated in cultured mammalian cells (Fig. 2a, c, e, g and i), and the sequence of the overhang appears not to contribute to target recognition<sup>9</sup>.

In co-transfection experiments, 25 nM siRNA duplexes were used (Figs 2 and 3); concentration is in respect to the final volume of tissue culture medium). Increasing the siRNA concentration to 100 nM did not enhance the specific silencing effects, but started to affect transfection efficiencies, perhaps due to competition for liposome encapsulation between plasmid DNA and siRNA (data not shown). Decreasing the siRNA concentration to 1.5 nM did not reduce the specific silencing effect (data not shown), even though the siRNAs were now only 2- to 20-fold more concentrated than the DNA plasmids; the silencing effect only vanishes completely if the siRNA concentration was dropped below 0.05 nM. This indicates that siRNAs are extraordinarily powerful reagents for mediating gene silencing, and that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene-targeting experiments<sup>20</sup>.

To monitor the effect of longer dsRNAs on mammalian cells, 50- and 500-bp dsRNAs that are cognate to the reporter genes were prepared. As a control for nonspecific inhibition, dsRNAs from humanized GFP (hG)<sup>21</sup> was used. In these experiments, the reporter plasmids were co-transfected with either 0.21 µg siRNA duplexes or 0.21 µg longer dsRNAs. The siRNA duplexes only reduced the expression of their cognate reporter gene, while the longer dsRNAs strongly and nonspecifically reduced reporter-gene expression. The effects are illustrated for HeLa S3 cells as a representative example (Fig. 3a and b). The absolute luciferase activities were decreased nonspecifically 10- to 20-fold by 50-bp dsRNA, and 20- to 200-fold by 500-bp dsRNA co-transfection, respectively. Similar nonspecific effects were observed for COS-7 and NIH/3T3 cells. For 293 cells, a 10- to 20-fold nonspecific reduction was observed only for 500-bp dsRNAs. Nonspecific reduction in reporter-gene expression by dsRNA > 30 bp was expected as part of the interferon response<sup>16</sup>. Interestingly, superimposed on the nonspecific interferon response, we detect additional sequence-specific, dsRNA-mediated silencing. The sequence-specific silencing effect of long dsRNAs, however, became apparent only when the relative reporter-gene activities were normalized to the hG dsRNA controls (Fig. 3c). Sequence-specific silencing by 50- or 500-bp dsRNAs reduced the targeted reporter-gene expression by an additional 2- to 5-fold. Similar effects were also detected in the other three mammalian cell lines tested (data not shown). Specific silencing effects with dsRNAs (356-1,662 bp) were previously reported in CHO-K1 cells, but the amounts of dsRNA required to detect a 2- to 4-fold specific reduction were about 20-fold higher than in our experiments<sup>12</sup>. Also, CHO-K1 cells appear to be deficient in the interferon response. In another report, 293, NIH/3T3 and BHK-21 cells were tested for RNAi using luciferase/β-galactosidase (lacZ) reporter combinations and 829-bp specific lacZ or 717-bp nonspecific green fluorescent protein (GFP) dsRNA<sup>22</sup>. The lack of detected RNAi in this case may be due to the less sensitive luciferase/lacZ reporter assay and the length differences of target and control dsRNA. Taken together, our results indicate that RNAi is active in mammalian cells, but that the silencing effect is difficult to detect if the interferon system is activated by dsRNA > 30 bp.

To test for silencing of endogenous genes, we chose four genes coding for cytoskeletal proteins: lamin A/C, lamin B1, nuclear mitotic apparatus protein (NuMA) and vimentin<sup>23</sup>. The selection was based on the availability of antibodies needed to quantitate the silencing effect. Silencing was monitored 40 to 45 h after transfection to allow for turnover of the protein of the targeted genes. As

shown in Fig. 4, the expression of lamin A/C was specifically reduced by the cognate siRNA duplex (Fig. 4a), but not when nonspecific siRNA directed against firefly luciferase (Fig. 4b) or buffer (Fig. 4c) was used. The expression of a non-targeted gene, NuMA, was unaffected in all treated cells (Fig. 4d-f), demonstrating the integrity of the targeted cells. The reduction in lamin A/C proteins was more than 90% complete as quantified by western blotting (Fig. 4j, k). We note that lamin A/C 'knock-out' mice are



**Figure 3** Effects of 21-nucleotide siRNAs, 50-bp, and 500-bp dsRNAs on luciferase expression in HeLa cells. The exact length of the long dsRNAs in base pairs is indicated below the bars. Experiments were performed with pGL2-Control and pRL-TK reporter plasmids. The data were averaged from two independent experiments  $\pm$  s.d. **a**, Absolute Pp-luc expression, plotted in arbitrary luminescence units (a.u.). **b**, R-luc expression, plotted in arbitrary luminescence units. **c**, Ratios of normalized target to control luciferase. The ratios of luciferase activity for siRNA duplexes were normalized to a buffer control (Bu, black bars); the luminescence ratios for 50- or 500-bp dsRNAs were normalized to the respective ratios observed for 50- and 500-bp dsRNAs from humanized GFP (hG, black bars). We note that the overall differences in sequence between the 49- and 484-bp GL2 and GL3 dsRNAs are not sufficient to confer specificity for targeting GL2 and GL3 targets (43-nucleotide uninterrupted identity in 49-bp segment, 239-nucleotide longest uninterrupted identity in 484-bp segment)<sup>30</sup>.

viable for a few weeks after birth<sup>23</sup> and that the lamin A/C knock-down in cultured cells was not expected to cause cell death. Lamin A and C are produced by alternative splicing in the 3' region and are present in equal amounts in the lamina of mammalian cells (Fig. 4j, k). Transfection of siRNA duplexes targeting lamin B1 and NuMA reduced the expression of these proteins to low levels (data not shown), but we were not able to observe a reduction in vimentin expression. This could be due to the high abundance of vimentin in the cells (several per cent of total cell mass) or because the siRNA sequence chosen was not optimal for targeting of vimentin.

The mechanism of the 21-nucleotide siRNA-mediated interference process in mammalian cells remains to be uncovered, and silencing might occur post-transcriptionally and/or transcriptionally. In *Drosophila* lysate, siRNA duplexes mediate post-transcriptional gene silencing by reconstitution of siRNA-protein complexes (siRNPs), which guide mRNA recognition and targeted cleavage<sup>27,28</sup>. In plants, dsRNA-mediated post-transcriptional silencing has also been linked to DNA methylation, which may also be directed by 21-

nucleotide siRNAs<sup>24</sup>. Methylation of promoter regions can lead to transcriptional silencing<sup>25</sup>, but methylation in coding sequences does not<sup>26</sup>. DNA methylation and transcriptional silencing in mammals are well documented processes<sup>27</sup>, yet their mechanisms have not been linked to that of post-transcriptional silencing. Methylation in mammals is predominantly directed towards CpG dinucleotide sequences. There is no CpG sequence in the RL or lamin A/C siRNA, although both siRNAs mediate specific silencing in mammalian cell culture, so it is unlikely that DNA methylation is essential for the silencing process.

Thus we have shown, for the first time, siRNA-mediated gene silencing in mammalian cells. The use of exogenous 21-nucleotide siRNAs holds great promise for analysis of gene function in human cell culture and the development of gene-specific therapeutics. It will also be of interest in understanding the potential role of endogenous siRNAs in the regulation of mammalian gene function. □

## Methods

### RNA preparation

21-nucleotide RNAs were chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides were deprotected and gel-purified. The accession numbers given below are from GenBank. The siRNA sequences targeting GL2 (Acc. No. X66324) and GL3 luciferase (Acc. No. U47296) corresponded to the coding regions 153–173 relative to the first nucleotide of the start codon; siRNAs targeting RL (Acc. No. AF025446) corresponded to region 119–139 after the start codon. The siRNA sequence targeting lamin A/C (Acc. No. X03444) was from position 608–630 relative to the start codon; lamin B1 (Acc. No. M05573) siRNA was from position 672–694; NuMA (Acc. No. Z11583) siRNA from position 3988–4010, and vimentin (Acc. No. NM\_003380) from position 346–368 relative to the start codon. Longer RNAs were transcribed with T7 RNA polymerase from polymerase chain reaction (PCR) products, followed by gel purification. The 49- and 484-bp GL2 or GL3 dsRNAs corresponded to positions 113–161 and 113–596, respectively, relative to the start of translation; the 50- and 501-bp RL dsRNAs corresponded to position 118–167 and 118–618, respectively. PCR templates for dsRNA synthesis targeting humanized GFP (hG) were amplified from pAD3 (ref. 21), whereby 50- and 501-bp hG dsRNA corresponded to positions 121–170 and 121–621, respectively, to the start codon.

For annealing of siRNAs, 20  $\mu$ M single strands were incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90 °C followed by 1 h at 37 °C. The 37 °C incubation step was extended overnight for the 50- and 500-bp dsRNAs, and these annealing reactions were performed at 8.4  $\mu$ M and 0.84  $\mu$ M strand concentrations, respectively.


### Cell culture

S2 cells were propagated in Schneider's *Drosophila* medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) 100 units ml<sup>-1</sup> penicillin, and 100  $\mu$ g ml<sup>-1</sup> streptomycin at 25 °C. 293, NIH/3T3, HeLa S3, HeLa S6, COS-7 cells were grown at 37 °C in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 units ml<sup>-1</sup> penicillin, and 100  $\mu$ g ml<sup>-1</sup> streptomycin. Cells were regularly passaged to maintain exponential growth. Twenty-four h before transfection at 50–80% confluency, mammalian cells were trypsinized and diluted 1:5 with fresh medium without antibiotics ( $1.3 \times 10^5$  cells ml<sup>-1</sup>) and transferred to 24-well plates (500  $\mu$ l per well). S2 cells were not trypsinized before splitting. Co-transfection of reporter plasmids and siRNAs was carried out with Lipofectamine 2000 (Life Technologies) as described by the manufacturer for adherent cell lines. Per well, 1.0  $\mu$ g pGL2-Control (Promega) or pGL3-Control (Promega), 0.1  $\mu$ g pRL-TK (Promega), and 0.21  $\mu$ g siRNA duplex or dsRNA, formulated into liposomes, were applied; the final volume was 600  $\mu$ l per well. Cells were incubated 20 h after transfection and appeared healthy thereafter. Luciferase expression was subsequently monitored with the Dual luciferase assay (Promega). Transfection efficiencies were determined by fluorescence microscopy for mammalian cell lines after co-transfection of 1.1  $\mu$ g hGFP-encoding pAD3 (ref. 21) and 0.21  $\mu$ g inverted GL2 siRNA, and were 70–90%. Reporter plasmids were amplified in XL-1 Blue (Stratagene) and purified using the Qiagen EndoFree Maxi Plasmid Kit.

Transfection of siRNAs for targeting endogenous genes was carried out using Oligofectamine (Life Technologies) and 0.84  $\mu$ g siRNA duplex per well, but it was recently found that as little as 0.01  $\mu$ g siRNAs per well are sufficient to mediate silencing. HeLa S6 cells were transfected one to three times in approximately 15 h intervals and were assayed 40 to 45 h after the first transfection. It appears, however, that a single transfection is as efficient as multiple transfections. Transfection efficiencies as determined by immunofluorescence of targeted cells were in the range of 90%. Specific silencing of targeted genes was confirmed by at least three independent experiments.

### Western blotting and immunofluorescence microscopy

Monoclonal 636 lamin A/C specific antibody<sup>29</sup> was used as undiluted hybridoma supernatant for immunofluorescence and 1/100 dilution for western blotting. Affinity-purified polyclonal NuMA protein 705 antibody<sup>30</sup> was used at a concentration of 10  $\mu$ g ml<sup>-1</sup> for



**Figure 4** Silencing of nuclear envelope proteins lamin A/C in HeLa cells. Triple fluorescence staining of cells transfected with lamin A/C siRNA duplex (a, d, g), with GL2 luciferase siRNA duplex (non-specific siRNA control) (b, e, h), and with buffer only (c, f, i). a–c, Staining with lamin A/C specific antibody; d–f, staining with NuMA-specific antibody; g–i, Hoechst staining of nuclear chromatin. Bright fluorescent nuclei in a represent untransfected cells. j, k, Western blots of transfected cells using lamin A/C (j) or vimentin-specific (k) antibodies. The Western blot was stripped and re-probed with vimentin antibody to check for equal loading of total protein.

immunofluorescence. Monoclonal V9 vimentin-specific antibody was used at 1/2000 dilution. For western blotting, transfected cells grown in 24-well plates were trypsinized and harvested in SDS sample buffer. Equal amounts of total protein were separated on 12.5% polyacrylamide gels and transferred to nitrocellulose. Standard immunostaining was carried out using ECL enhanced chemiluminescence technique (Amersham Pharmacia).

For immunofluorescence, transfected cells grown on glass coverslips in 24-well plates were fixed in methanol for 6 min at  $-10^{\circ}\text{C}$ . Target gene specific and control primary antibodies were added and incubated for 80 min at  $37^{\circ}\text{C}$ . After washing in phosphate buffered saline (PBS), Alexa 488-conjugated anti-rabbit (Molecular Probes) and Cy3-conjugated anti-mouse (Dianova) antibodies were added and incubated for 60 min at  $37^{\circ}\text{C}$ . Finally, cells were stained for 4 min at room temperature with Hoechst 33342 (1  $\mu\text{M}$  in PBS) and embedded in Mowiol 488 (Rochem). Pictures were taken with a Zeiss AxioPhot camera with a Fluor 40/1.30 oil objective and MetaMorph Imaging Software (Universal Imaging Corporation) with equal exposure times for the specific antibodies.

Received 30 February; accepted 26 April 2001.

1. Fire, A. RNA-triggered gene silencing. *Trends Genet.* **15**, 358–363 (1999).
2. Sharp, P. A. RNA interference. *2001. Genes Dev.* **15**, 485–490 (2001).
3. Hammond, S. M., Caudy, A. A. & Vannoy, G. J. Post-transcriptional gene silencing by double-stranded RNA. *Nature Rev. Genet.* **2**, 110–119 (2001).
4. Tuschli, T. RNA interference and small interfering RNAs. *Chem. Biochem.* **2**, 239–245 (2001).
5. Hamilton, A. J. & Baulcombe, D. C. A species of small antisense RNA in posttranscriptional gene silencing in plants. *Science* **286**, 950–952 (1999).
6. Hammond, S. M., Bernatien, E., Beach, D. & Hannon, G. J. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* **404**, 293–296 (2000).
7. Zamore, P. D., Tuschli, T., Sharp, P. A. & Bartel, D. P. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* **101**, 25–33 (2000).
8. Bernstein, E., Caudy, A. A., Hammond, S. M. & Hannon, G. J. Role for a bidirectional ribonuclease in the initiation step of RNA interference. *Nature* **409**, 363–366 (2001).
9. Ehsalati, S. M., Lasek, W. & Tuschli, T. RNA interference is mediated by 21 and 22 nt RNAs. *Genes Dev.* **15**, 148–160 (2001).
10. Caplan, N. J., Fieson, J., Fire, A. & Morgan, R. A. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. *Genes Dev.* **15**, 95–105 (2000).
11. Clements, J. C. et al. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. *Proc. Natl Acad. Sci. USA* **97**, 6499–6503 (2000).
12. Ullrich, K., Zennaro, S., Miyata, T. & Salign, K. Sensitive assay of RNA interference in *Drosophila* and Chinese hamster ovary cells using firefly luciferase gene as target. *FEBS Lett.* **479**, 79–82 (2000).
13. Wianey, F. & Zernicka-Goetz, M. Specific interference with gene function by double-stranded RNA in early mouse development. *Nature Cell Biol.* **2**, 70–75 (2000).
14. Svoboda, P., Stein, P., Hayashi, H. & Schultz, R. M. Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. *Development* **127**, 4147–4156 (2000).
15. Behrmann, M. B. & Zariw, H. Transcriptional and posttranscriptional silencing of rodent alpha(I) collagen by a homologous transcriptionally self-silenced transgene. *Mol. Cell Biol.* **19**, 274–283 (1999).
16. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. *Annu. Rev. Biochem.* **67**, 227–264 (1998).
17. Mancho, L., Green, S. R., Schmidt, C. & Matsumura, M. B. Interactions between double-stranded RNA regulators and the protein kinase DAI. *Mol. Cell Biol.* **13**, 5238–5248 (1993).
18. Mink, M. A., Wiet, D. K., Benveniste, S. & Baglioni, C. Structural requirements of double-stranded RNA for the activation of 2',5'-oligoadenylate polymerase and protein kinase of interferon-treated HeLa cells. *J. Biol. Chem.* **254**, 10180–10183 (1979).
19. Clements, M. & Williams, B. Inhibition of cell-free protein synthesis by ppvA<sup>+</sup> p<sup>+</sup> p<sup>+</sup> A: a novel oligonucleotide synthesized by interferon treated cell extracts. *Cell* **58**, 1469–1470 (1979).
20. Maciej, D. G. et al. Inhibition of hepatitis C virus (HCV) RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic antibody ribozymes. *Hepatology* **31**, 769–776 (2000).
21. Kehlenbach, R. H., Diekmann, A. & Gericke, L. Nucleocytoplasmic shuttling factors including Ran and CRM1 mediate nuclear export of NTA1 in vitro. *J. Cell Biol.* **141**, 863–874 (1998).
22. Kravtsov, T. & Vale, R. *Guidebook to the Cytoskeleton and Motor Proteins*, Parts 2 and 3 (Oxford Univ. Press, Oxford, 1999).
23. Sullivan, T. et al. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. *J. Cell Biol.* **147**, 913–920 (1999).
24. Waernegger, M. RNA-directed DNA methylation. *Plant Mol. Biol.* **43**, 203–220 (2000).
25. Mette, M. F., Aufsatz, W., von der Wenden, J., Matzke, M. A. & Matzke, A. J. M. Transcriptional silencing and promoter methylation triggered by double-stranded RNA. *EMBO J.* **19**, 5214–5221 (2000).
26. Wang, M.-B., Wesley, S. V., Finnegan, E. J., Smith, N. A. & Waterhouse, P. M. Replicating satellite RNA induces sequence-specific DNA methylation and truncated transcripts in plants. *RNA* **7**, 16–28 (2001).
27. Kazin, A. CpG methylation, chromatin structure and gene silencing—a three-way connection. *EMBO J.* **17**, 4905–4908 (1998).
28. Robert, R., Gieseler, R. K., Peters, J. H., Weber, K. & Osborn, M. Induction of nuclear lamin A/C in macrophages in vitro cultures of rat bone marrow precursor cells and human blood monocytes, and in macrophages elicited in vivo by thioglycollate stimulation. *Exp. Cell Res.* **190**, 185–194 (1990).
29. Harborth, J., Wang, J., Guth-Hallonet, C., Weber, K. & Osborn, M. Self assembly of NuA4: multimer oligomers as structural units of a nuclear lattice. *EMBO J.* **18**, 1769–1780 (1999).
30. Parikh, S., Herten, J., Xu, S., A. & Fire, A. Functional anatomy of a dsRNA trigger: Differential requirement for the two trigger strands in RNA interference. *Mol. Cell* **6**, 1077–1087 (2000).

#### Acknowledgements

We thank J. Martinez, J. Ludwig and D. Bartel for comments on the manuscript; L. Fredel for help with image processing; H.-J. Dehne for technical assistance; R. Döring, R. Nehring,

D. Ingelfinger and C. Schneider for supplying cell lines; A. Dickmanns for the gift of the plasmid pAD3; and R. Lührmann for support. This work was funded by a Biofuture grant of the Bundesministerium für Bildung und Forschung.

Correspondence and requests for materials should be addressed to T.T. (e-mail: ttuschli@mpibpc.gwdg.de).

## Ribosomal peptidyl transferase can withstand mutations at the putative catalytic nucleotide

Horbert Polacek, Marnie Gaynor, Aymen Yassin & Alexander S. Mankin

Center for Pharmaceutical Biotechnology (MC 870), University of Illinois, 900 South Ashland Avenue, Chicago, Illinois 60607, USA

Peptide bond formation is the principal reaction of protein synthesis. It takes place in the peptidyl transferase centre of the large (50S) ribosomal subunit. In the course of the reaction, the polypeptide is transferred from peptidyl transfer RNA to the  $\alpha$ -amino group of amino acyl-tRNA. The crystallographic structure of the 50S subunit showed no proteins within 18 Å from the active site, revealing peptidyl transferase as an RNA enzyme<sup>1</sup>. Reported unique structural and biochemical features of the universally conserved adenine residue A2451 in 23S ribosomal RNA (*Escherichia coli* numbering) led to the proposal of a mechanism of rRNA catalysis that implicates this nucleotide as the principal catalytic residue<sup>2,3</sup>. *In vitro* genetics allowed us to test the importance of A2451 for the overall rate of peptide bond formation. Here we report that large ribosomal subunits with mutated A2451 showed significant peptidyl transferase activity in several independent assays. Mutations at another nucleotide, G2447, which is essential to render catalytic properties to A2451 (refs 2, 3), also did not dramatically change the transpeptidation activity. As alterations of the putative catalytic residues do not severely affect the rate of peptidyl transfer the ribosome apparently promotes transpeptidation not through chemical catalysis, but by properly positioning the substrates of protein synthesis. The proposed role of A2451 in the peptidyl transfer reaction is

